Form 4: Catalyst Pharmaceuticals Executive Sundaram Reports Stock Transactions

Preethi Sundaram, Chief Strategy Officer at Catalyst Pharmaceuticals, reports the vesting and subsequent tax withholding related to restricted stock units.

Summary

• On February 14, 2025, Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, had restricted stock units vest, resulting in the acquisition of 16,667 shares of common stock.
• Simultaneously, 5,965 shares were withheld by the company to cover applicable withholding taxes.
• Following these transactions, Sundaram directly owns 45,005 shares of Catalyst Pharmaceuticals common stock.
• The reported transactions relate to the vesting of restricted stock units granted previously, which vested in three equal tranches on February 14, 2023, February 14, 2024, and February 14, 2025.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation and does not inherently indicate positive or negative sentiment. It reflects standard corporate governance and compensation practices.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which is important for maintaining investor confidence and ensuring fair markets.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive compensation and stock ownership.
• The transactions have a minimal impact on the overall share structure of the company.

Key Dates